Presented By Daniel Renouf at 2021 Gastrointestinal Cancers … · 2021. 1. 19. · Secondary...
6
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)<br /> Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
Transcript of Presented By Daniel Renouf at 2021 Gastrointestinal Cancers … · 2021. 1. 19. · Secondary...
-
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Background:
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 3
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 4
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 5
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
-
Slide 6
Presented By Daniel Renouf at 2021 Gastrointestinal Cancers Symposium
